Sensei Biotherapeutics Gets Wall Street Backing as PIKTOR Advances in Breast & Endometrial Cancer

Cantor is bullish on Sensei Biotherapeutics for its cancer drug PIKTOR, with Phase 2 data soon as a key stock catalyst.